ELOXX PHARMACEUTICALS, INC. — Operating Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6dcde7ac-3894-4348-ad60-e87bf924bc51/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-6.4M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-108687 |
| FY 2024 | $-2.5M | 2024-01-01 – 2024-12-31 | evidence 0001193125-26-108687 |
| FY 2023 | $-17.3M | 2023-01-01 – 2023-12-31 | evidence 0001193125-26-108687 |
| FY 2022 | $-34.4M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-011360 |
| FY 2021 | $-66.0M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-012683 |
| FY 2020 | $-33.5M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-012703 |
| FY 2019 | $-50.6M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-009148 |
| FY 2018 | $-47.6M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-007811 |
| FY 2017 | $-20.4M | 2017-01-01 – 2017-12-31 | evidence 0001193125-18-086028 |
| FY 2016 | $-9.8M | 2016-01-01 – 2016-12-31 | evidence 0001193125-18-086028 |
| FY 2015 | $-6.3M | 2015-01-01 – 2015-12-31 | evidence 0001193125-18-086028 |
| FY 2014 | $-9.1M | 2013-07-01 – 2014-06-30 | evidence 0001144204-14-058176 |
| FY 2013 | $-63.1M | 1998-07-01 – 2014-03-31 | evidence 0001144204-14-029005 |
| FY 2012 | $-54.7M | 1998-07-01 – 2013-03-31 | evidence 0001144204-13-029119 |
| FY 2011 | $-49.8M | 1998-07-01 – 2012-03-31 | evidence 0001144204-12-028430 |
| FY 2010 | $-4.8M | 2009-07-01 – 2010-06-30 | evidence 0001144204-12-057875 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ELOXX PHARMACEUTICALS, INC. — all facts · Revenue · Net Income